Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

HIV Protease Antikörper

Reaktivität: Human Immunodeficiency Virus (HIV) ELISA, WB, Func Wirt: Maus Monoclonal 1696 unconjugated
Produktnummer ABIN125709
  • Target
    HIV Protease
    Reaktivität
    • 2
    • 1
    Human Immunodeficiency Virus (HIV)
    Wirt
    • 3
    Maus
    Klonalität
    • 3
    Monoklonal
    Konjugat
    • 3
    Unkonjugiert
    Applikation
    ELISA, Western Blotting (WB), Functional Studies (Func)
    Spezifität
    The antibody 1696 recognizes free N-terminus of mature HIV protease (HIV-1 and HIV-2), an enzyme that hydrolyzes polyproteins of HIV viruses into functional proteins. The antibody 1696 does not react with the precursor.
    Kreuzreaktivität (Details)
    HIV
    Aufreinigung
    Purified by protein-A affinity chromatography.
    Reinheit
    > 95 % (by SDS-PAGE)
    Immunogen
    Bacterially expressed full-length HIV-1 protease
    Klon
    1696
    Isotyp
    IgG1
  • Applikationshinweise
    Functional application: The antibody 1696 strongly inhibits the enzyme activity of HIV-1 and HIV-2 proteases.
    Western blotting: Recommended dilution: 0.5 μg/mL.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Konzentration
    1 mg/mL
    Buffer
    Phosphate buffered saline (PBS), pH 7.4
    Konservierungsmittel
    Azide free
    Handhabung
    Do not freeze.
    Lagerung
    4 °C
    Informationen zur Lagerung
    Store at 2-8°C. Do not freeze.
  • Dunn, Boyer, McWilliams, Smith, Hughes: "Mutations in human immunodeficiency virus type 1 reverse transcriptase that make it sensitive to degradation by the viral protease in virions are selected against in patients." in: Virology, Vol. 484, pp. 127-35, (2015) (PubMed).

    Dunn, Boyer, Clark, Hughes: "Mutations in HIV-1 reverse transcriptase cause misfolding and miscleavage by the viral protease." in: Virology, (2013) (PubMed).

    Bartonová, Král, Sieglová, Brynda, Fábry, Horejsí, Kozísek, Sasková, Konvalinka, Sedlácek, Rezácová: "Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies." in: Antiviral research, Vol. 78, Issue 3, pp. 275-7, (2008) (PubMed).

    OLoughlin, Greene, Matsumura: "Diversification and specialization of HIV protease function during in vitro evolution." in: Molecular biology and evolution, Vol. 23, Issue 4, pp. 764-72, (2006) (PubMed).

    Lescar, Brynda, Rezacova, Stouracova, Riottot, Chitarra, Fabry, Horejsi, Sedlacek, Bentley: "Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody." in: Protein science : a publication of the Protein Society, Vol. 8, Issue 12, pp. 2686-96, (2000) (PubMed).

  • Target
    HIV Protease
    Substanzklasse
    Viral Protein
    Hintergrund
    The HIV protease (PR) hydrolyzes polyproteins of HIV virus into functional protein products that are essential for its assembly and subsequent activity. This maturation process occurs as the virion buds from the host cell. HIV protease inhibitors are used in the treatment of patients with AIDS and were considered the first breakthrough in over a decade of AIDS research. HIV protease inhibitors can lower the viral load carried by AIDS patents.,HIV-1 PR, HIV-2 PR
Sie sind hier:
Kundenservice